Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT03411252
Other study ID # 17P.054
Secondary ID
Status Terminated
Phase Early Phase 1
First received
Last updated
Start date February 15, 2018
Est. completion date December 15, 2019

Study information

Verified date March 2021
Source Thomas Jefferson University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study evaluates whether a medication called mirabegron is better than placebo (sugar pill) in helping patients with achalasia swallow better. Each patient will receive either mirabegron or the placebo for 4 weeks followed by the opposite medication. Each patient will complete several surveys and undergo several tests to determine if the mirabegron is helping reduce the pressures in the esophagus (swallowing tube).


Description:

Achalasia is characterized by incomplete or absent relaxation of the lower esophageal sphincter (LES) and loss of esophageal peristalsis which leads to dysphagia. Standard of care for achalasia includes endoscopic management (dilation and injection of injection of botulinum toxin) and surgery, however both of these options carry procedural risks, may lose efficacy over time and many patients are not appropriate candidates for these treatment options. Unfortunately, there are limited oral medications for patients with achalasia. Mirabegron is an oral beta-3 agonist currently FDA approved for overactive bladder that works by relaxing the bladder muscles. Beta-3 receptors have also been identified in the LES with stimulation leading to LES relaxation in preclinical studies. Through a proof of concept pilot study, the investigators aim to evaluate the effect of mirabegron in patients with achalasia via high resolution manometry and a validated dysphagia scale.


Recruitment information / eligibility

Status Terminated
Enrollment 5
Est. completion date December 15, 2019
Est. primary completion date December 15, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - 18 years old < Age < 75 years old with prior diagnosis of achalasia via manometry and/or radiographically Exclusion Criteria: - < 18 years old or > 75 years old - History of hypertension not controlled on oral medications (blood pressure > 160/100 mm Hg) - No prior history of hypertension with a blood pressure > 160/100 mm Hg - History of bladder outlet obstruction - History of angioedema - Pregnant or breast-feeding women: Women between 18 and 40 years old who are enrolled in the study will be required to use a form of birth control during the study - Patients currently receiving certain medications (digoxin, warfarin, any overactive bladder medications, thioridazine, flecainide, propafenone, phosphodiesterase inhibitors) - Patients with prolonged QTc interval or risk factors to develop it: - Baseline QTc on EKG of > 450 milliseconds - History of additional risk factors for Torsades de Pointes (heart failure, family history of long QT syndrome) - Concomitant medications that prolong the QTc interval: ranolazine, sotalol, dofetilide, procainamide, disopyramide, propafenone, azole antifungals, fluoroquinolones, macrolide antibiotics, HIV antiretrovirals, chemotherapy, beta-2 agonists, tricyclic antidepressants, selective serotonin reuptake inhibitors - Prior surgeries for achalasia - < 2 months since last endoscopic botulinum toxin injection into LES or endoscopic dilation - Stage 4 Chronic kidney disease (severe renal impairment with GFR 15-29 ml/min), Stage 5 Chronic Kidney disease (GFR < 15 ml/min or on dialysis) - Childs Pugh B (moderate) or C (severe) Cirrhotic (hepatic impairment)

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Mirabegron 50 MG
Myrbetriq (Mirabegron) tablet
Placebo
Sugar pill manufactured to mimic Mirabegron

Locations

Country Name City State
United States Thomas Jefferson University Philadelphia Pennsylvania

Sponsors (2)

Lead Sponsor Collaborator
Thomas Jefferson University Astellas Pharma Inc

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Changes in lower esophageal sphincter pressures Evaluation of changes in lower esophageal sphincter pressures using high resolution manometry Change in lower esophageal sphincter pressure from baseline after 4 weeks of placebo or Mirabegron
Secondary Eckardt Achalasia Score (EAS) Patients will complete the Eckardt Achalasia score which is a simple written scale evaluating dysphagia, regurgitation, retrosternal pain and weight loss. Patients report their symptoms from a 0 to 3. Weight loss (0-none, 1: < 5 kg, 2: 5-10 kg, 3: > 10 kg), Dysphagia (0-none, 1-occasional, 2-daily, 3-each meal), Retrosternal pain (0-none, 1-occasional, 2-daily, 3-each meal), Regurgitation (0-none, 1-occasional, 2-daily, 3-each meal). The value for each of the 4 categories is added together to give the EAS. This EAS will be reported for each time point below. A higher score is consistent with worse achalasia and worse outcomes. A lower score is consistent with less severe achalasia and better outcomes. The total range is 0 (no symptoms) to 12 (severe symptoms). There are no subscales. Patients will complete the EAS on study day -14, 0, 7, 28, 42, 49, 70, 84. We will evaluate changes in patient's EAS between day 0 and all of these time points.
See also
  Status Clinical Trial Phase
Completed NCT01399476 - Endoscopic Myotomy of the Lower Esophageal Sphincter for Achalasia N/A
Recruiting NCT05326113 - The Effect of Physiotherapy on Post POEM Reflux N/A
Recruiting NCT06044155 - redoPOEM : Failure of a First POEM
Recruiting NCT02989883 - Clinical Outcomes of Peroral Endoscopic Myotomy N/A
Terminated NCT02606578 - Achalasia Patient Reported Outcomes
Recruiting NCT01793922 - POEM Trial: Multi-center Study Comparing Endoscopic Pneumodilation and Per Oral Endoscopic Myotomy (POEM) N/A
Recruiting NCT01302288 - Endolumenal Partial Myotomy for the Treatment of Esophageal Achalasia Phase 2
Terminated NCT03875365 - Institutional Outcome Data From Per-oral Plication of the Esophagus
Enrolling by invitation NCT02770859 - Per-Oral Endoscopic Myotomy (POEM) for the Treatment of Achalasia, Database Repository
Recruiting NCT05905016 - Prospective Evaluation of the Clinical Utility of Peroral Endoscopic Myotomy for Gastrointestinal Motility Disorders
Completed NCT01692106 - A Clinical Study of Per Oral Endoscopic Myotomy (POEM) in Patients Suffering From Achalasia N/A
Completed NCT01405469 - Endoscopic Peroral Myotomy for Treatment of Achalasia N/A
Completed NCT01402518 - Per-Oral Endoscopic Myotomy
Not yet recruiting NCT00790465 - Efficacy of Dark Chocolate in Achalasia Patients Phase 1/Phase 2
Recruiting NCT01799967 - Minimally Invasive Surgery of the Gastro-esophageal Junction
Terminated NCT00604942 - vMII for Measurement of Oesophageal Bolus Transport and Reflux N/A
Recruiting NCT06405412 - Effects of Malnutrition on Respiratory and Renal Functions in Patients Undergoing Peroral Endoscopic Myotomy (POEM) N/A
Not yet recruiting NCT06042127 - POEM-F for Achalasia International Study N/A
Completed NCT04752670 - ConMed Beamer Study
Completed NCT02314741 - Peroral Endoscopic Myotomy (POEM) for Esophageal Motility N/A